Drugs / MVA Brachyury-TRICOM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02179515 | Jun 2014 → Apr 2017 | breast cancer, lung cancer, ovarian cancer, prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-brachyury- TRICOM | “Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)” NCT02179515 ↗1“Modified vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM)” NCT02179515 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT02179515 ↗ |